{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:03:27Z","timestamp":1790949807666,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00774-025-01590-2","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:43:18Z","timestamp":1740804198000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Sequential and combination therapy with romosozumab"],"prefix":"10.1007","volume":"43","author":[{"given":"Tomonori","family":"Kobayakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"1590_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T Sozen","year":"2017","unstructured":"Sozen T, Ozisik L, Basaran NC (2017) An overview and management of osteoporosis (in eng). Eur J Rheumatol 4:46\u201356. https:\/\/doi.org\/10.5152\/eurjrheum.2016.048","journal-title":"Eur J Rheumatol"},{"key":"1590_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures (in eng). Osteoporos Int 17:1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"1590_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Al Nofal A, Haydour Q, Wang Z, Murad MH (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis (in Eng). J Clin Endocrinol Metab 104:1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2019-00192","journal-title":"J Clin Endocrinol Metab"},{"key":"1590_CR4","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1001\/archinte.1991.00400100100017","volume":"151","author":"EA Chrischilles","year":"1991","unstructured":"Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact (in Eng). Arch Intern Med 151:2026\u20132032","journal-title":"Arch Intern Med"},{"key":"1590_CR5","doi-asserted-by":"publisher","first-page":"185S","DOI":"10.1016\/8756-3282(95)00500-5","volume":"18","author":"DT Gold","year":"1996","unstructured":"Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis (in Eng). Bone 18:185S-S189. https:\/\/doi.org\/10.1016\/8756-3282(95)00500-5","journal-title":"Bone"},{"key":"1590_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jamda.2012.10.013","volume":"14","author":"J Visschedijk","year":"2013","unstructured":"Visschedijk J, van Balen R, Hertogh C, Achterberg W (2013) Fear of falling in patients with hip fractures: prevalence and related psychological factors (in Eng). J Am Med Dir Assoc 14:218\u2013220. https:\/\/doi.org\/10.1016\/j.jamda.2012.10.013","journal-title":"J Am Med Dir Assoc"},{"key":"1590_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","volume":"90","author":"A Singer","year":"2015","unstructured":"Singer A, Exuzides A, Spangler L, O\u2019Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States (in Eng). Mayo Clin Proc 90:53\u201362. https:\/\/doi.org\/10.1016\/j.mayocp.2014.09.011","journal-title":"Mayo Clin Proc"},{"key":"1590_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s001980070075","volume":"11","author":"JA Cauley","year":"2000","unstructured":"Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures (in Eng). Osteoporos Int 11:556\u2013561. https:\/\/doi.org\/10.1007\/s001980070075","journal-title":"Osteoporos Int"},{"key":"1590_CR9","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group (1994) (in Eng). World Health Organization technical report series 843:1\u2013129"},{"key":"1590_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","volume":"18","author":"R Marcus","year":"2003","unstructured":"Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis (in Eng). J Bone Miner Res 18:18\u201323. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.18","journal-title":"J Bone Miner Res"},{"key":"1590_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00774-010-0188-x","volume":"29","author":"M Shiraki","year":"2011","unstructured":"Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K et al (2011) Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP) (in Eng). J Bone Miner Metab 29:37\u201343. https:\/\/doi.org\/10.1007\/s00774-010-0188-x","journal-title":"J Bone Miner Metab"},{"key":"1590_CR12","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures (in Eng). J Clin Endocrinol Metab 90:1583\u20131587. https:\/\/doi.org\/10.1210\/jc.2004-0826","journal-title":"J Clin Endocrinol Metab"},{"key":"1590_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis F (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women (in Eng). Osteoporos Int 30:3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"key":"1590_CR14","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2012.13624","volume":"142","author":"K Lippuner","year":"2012","unstructured":"Lippuner K (2012) The future of osteoporosis treatment - a research update (in Eng). Swiss Med Wkly 142:w13624. https:\/\/doi.org\/10.4414\/smw.2012.13624","journal-title":"Swiss Med Wkly"},{"key":"1590_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/JBMR.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate (in Eng). J Bone Miner Res 19:745\u2013751. https:\/\/doi.org\/10.1359\/JBMR.040117","journal-title":"J Bone Miner Res"},{"key":"1590_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial (in Eng). Lancet 386:1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"key":"1590_CR17","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent (in Eng). J Clin Endocrinol Metab 94:3772\u20133780. https:\/\/doi.org\/10.1210\/jc.2008-2719","journal-title":"J Clin Endocrinol Metab"},{"key":"1590_CR18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A (2018) Effects of 24 Months of treatment with romosozumab followed by 12 Months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, Double-Blind, Phase 2, Parallel Group Study (in Eng). J Bone Miner Res 33:1397\u20131406. https:\/\/doi.org\/10.1002\/jbmr.3452","journal-title":"J Bone Miner Res"},{"key":"1590_CR19","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","volume":"31","author":"MR McClung","year":"2020","unstructured":"McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab (in Eng). Osteopor Int 31:2231\u20132241. https:\/\/doi.org\/10.1007\/s00198-020-05502-0","journal-title":"Osteopor Int"},{"key":"1590_CR20","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis (in Eng). N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"1590_CR21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis (in Eng). N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"1590_CR22","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial (in Eng). Lancet 390:1585\u20131594. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6","journal-title":"Lancet"},{"key":"1590_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1620\/tjem.239.17","volume":"239","author":"M Kamimura","year":"2016","unstructured":"Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H (2016) Bisphosphonate pre-treatment diminishes the therapeutic benefits of teriparatide in japanese osteoporotic patients (in Eng). Tohoku J Exp Med 239:17\u201324. https:\/\/doi.org\/10.1620\/tjem.239.17","journal-title":"Tohoku J Exp Med"},{"key":"1590_CR24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/14656566.2016.1176147","volume":"17","author":"L Gennari","year":"2016","unstructured":"Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D (2016) Treatment needs and current options for postmenopausal osteoporosis (in Eng). Expert Opin Pharmacother 17:1141\u20131152. https:\/\/doi.org\/10.1080\/14656566.2016.1176147","journal-title":"Expert Opin Pharmacother"},{"key":"1590_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Hirao M, Okamura G, Etani Y, Takami K, Goshima A, Miura T, Nakata K, Okada S (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis (in Eng). Joint Bone Spine 88:105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"key":"1590_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","volume":"14","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J, Nakamura Y (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study (in Eng). Bone Rep 14:101068. https:\/\/doi.org\/10.1016\/j.bonr.2021.101068","journal-title":"Bone Rep"},{"key":"1590_CR27","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study (in Eng). Osteoporos Int 32:1999\u20132009. https:\/\/doi.org\/10.1007\/s00198-021-05925-3","journal-title":"Osteoporos Int"},{"key":"1590_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00774-023-01477-0","volume":"42","author":"A Miyauchi","year":"2024","unstructured":"Miyauchi A, Hamaya E, Shimauchi J, Yoshinaga Y, Nishi K (2024) Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study (in Eng). J Bone Miner Metab 42:77\u201389. https:\/\/doi.org\/10.1007\/s00774-023-01477-0","journal-title":"J Bone Miner Metab"},{"key":"1590_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One Year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension Study (in Eng). J Bone Miner Res 34:419\u2013428. https:\/\/doi.org\/10.1002\/jbmr.3622","journal-title":"J Bone Miner Res"},{"key":"1590_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116480","volume":"162","author":"T Kobayakawa","year":"2022","unstructured":"Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y (2022) Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: the prospective VICTOR study (in Eng). Bone 162:116480. https:\/\/doi.org\/10.1016\/j.bone.2022.116480","journal-title":"Bone"},{"key":"1590_CR31","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00198-022-06386-y","volume":"33","author":"K Ebina","year":"2022","unstructured":"Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, Kunugiza Y, Hirao M, Okamura G, Noguchi T, Takami K, Goshima A, Miura T, Fukuda Y, Kurihara T, Okada S, Nakata K (2022) Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis (in Eng). Osteoporos Int 33:1807\u20131813. https:\/\/doi.org\/10.1007\/s00198-022-06386-y","journal-title":"Osteoporos Int"},{"key":"1590_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00223-023-01079-y","volume":"112","author":"T Oue","year":"2023","unstructured":"Oue T, Shimizu T, Asano T, Shimodan S, Ishizu H, Arita K, Iwasaki N (2023) Comparison of the efficacy of zoledronate acid or denosumab after switching from romosozumab in Japanese postmenopausal patients (in Eng). Calcif Tissue Int 112:683\u2013690. https:\/\/doi.org\/10.1007\/s00223-023-01079-y","journal-title":"Calcif Tissue Int"},{"key":"1590_CR33","doi-asserted-by":"publisher","unstructured":"Kobayakawa T, Kanayama Y, Hirano Y, Yukishima T, Nakamura Y (2024) Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab (in Eng). JBMR plus 8:ziae131 https:\/\/doi.org\/10.1093\/jbmrpl\/ziae131","DOI":"10.1093\/jbmrpl\/ziae131"},{"key":"1590_CR34","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE, Libanati C, Ferrari S (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence (in Eng). Osteopor Int 33:1243\u20131256. https:\/\/doi.org\/10.1007\/s00198-021-06174-0","journal-title":"Osteopor Int"},{"key":"1590_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.clnesp.2022.02.002","volume":"48","author":"T Kobayakawa","year":"2022","unstructured":"Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y (2022) Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis (in Eng). Clin Nutrit ESPEN 48:267\u2013274. https:\/\/doi.org\/10.1016\/j.clnesp.2022.02.002","journal-title":"Clin Nutrit ESPEN"},{"key":"1590_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae016","author":"G Adami","year":"2024","unstructured":"Adami G, Pedrollo E, Rossini M, Fassio A, Braga V, Pasetto E, Pollastri F, Benini C, Viapiana O, Gatti D (2024) Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study (in Eng). JBMR Plus. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae016","journal-title":"JBMR Plus"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01590-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01590-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01590-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T17:02:50Z","timestamp":1743440570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01590-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1590"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01590-2","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since this manuscript is a review article, it is not subject to the ethical standards of the institutional and\/or national research committees or to the 1964 Helsinki Declaration and its subsequent amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}